Novartis has revealed that the FDA has accepted its resubmission for cholesterol-lowering drug Leqvio – rejected unexpectedly by the US regulator last year – and has set a new action date of 1 ...

Novartis has a long way to go to make its twice-yearly cholesterol-lowering drug Leqvio the multi-billion-dollar blockbuster it is predicting – but took another step along that road today.

Leqvio put up a strong performance in the United States. Solid uptake in markets such as Germany and China is also fueling sales. Novartis obtained global rights to develop, manufacture and ...

Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of ...

Novartis possesses an AA- credit rating from ... The bad cholesterol-lowering drug branded Leqvio generated the highest percentage growth rate, with net sales soaring approximately 81% year ...

Recently launched drugs Leqvio, Scemblix, Lutathera, Fabhalta and Pluvicto came in line with the board’s sales targets. In 2024, Novartis signed 24 business development deals, although the ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Novartis’ efforts to strengthen its wide portfolio by developing breakthrough treatments have made it even more formidable in this space. Kesimpta, Pluvicto, Scemblix, Kisqali, Leqvio and ...

Key drugs like Kisqali (breast cancer), Kesimpta (multiple sclerosis), Scemblix (chronic myeloid leukemia or CML), Pluvicto (prostate cancer), Leqvio (cholesterol) and Fabhalta (paroxysmal nocturnal ...